Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of <3 Hour Intravenous Alteplase.

Katherine T MunJordan B BonomoDavid S Liebeskind Jeffrey L Saver

Published in: Stroke (2022)

Within-3-hour intravenous alteplase for acute ischemic stroke is one of the most robustly proven therapies in medicine. The initial concurrent trials 25 years ago showed robust evidence for benefit and, after additional studies, advanced to highly robust.

Keyphrases

acute ischemic stroke
blood pressure
high dose
systematic review
squamous cell carcinoma
low dose
case control
hip fracture